Fate Therapeutics (FATE) Tops Q3 EPS by 10c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.46), $0.10 better than the analyst estimate of ($0.56). Revenue for the quarter came in at $1.94 million versus the consensus estimate of $1.59 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Paramount Global (PARA) Tops Q2 EPS by 480c
• Cue Biopharma, Inc. (CUE) Misses Q2 EPS by 2054c